Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3720228 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL29788546 | 0.87 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL520427 | 0.87 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL31090163 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL16233087 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL8297975 | 0.85 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL28712446 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL6489059 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL4512978 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL1667910 | 0.83 | TTR (0.68) | SMN1; SMN2ALDH1A1LMNAHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692096-A1 | MACROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Prime Gene Therapeutics Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12479834-B2 | Phenol compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2025-09-04 | — | — | US | disclosed |
| CN-119977833-A | Synthesis and antitumor application of erianin derivative | 江苏海洋大学 | 2025-05-13 | — | — | CN | disclosed |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| CN-113811534-B | TYK2 inhibitors and uses thereof | 阿鲁米斯公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024199479-A1 | MACROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-114591351-B | Polycyclic compound and preparation method and application thereof | 成都科岭源医药技术有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| EP-4067343-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-10-05 | — | — | EP | disclosed |
| US-20030220404-A1 | Process for the preparation of combretastatins | AVENTIS PHARMA S.A. (FR) | 2003-11-27 | — | — | US | disclosed |
| US-20030187068-A1 | Substituted phenylpropionic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| WO-2003072062-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-09-04 | — | — | WO | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| EP-1285908-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-02-26 | — | — | EP | disclosed |
| EP-1196391-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005770-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-25 | — | — | WO | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| US-5952362-A | INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY | SYNTEX (U.S.A) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | SMN1; SMN2 1274/4885ALDH1A1 4098/4885LMNA 3948/4885 |
| US-20030187068-A1 | Substituted phenylpropionic acid derivatives | PPARA, PPARG, PPARD | SMN1; SMN2 4657/4885ALDH1A1 429/4885LMNA 2358/4885 |
| US-20030220404-A1 | Process for the preparation of combretastatins | TGFB2, HMGCR, TGFB1 | SMN1; SMN2 1402/4885ALDH1A1 2753/4885LMNA 277/4885 |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | SMN1; SMN2 4581/4885ALDH1A1 508/4885LMNA 4684/4885 |
| US-12479834-B2 | Phenol compound or salt thereof | REN, MLX, MYB | SMN1; SMN2 3261/4885ALDH1A1 287/4885LMNA 1482/4885 |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | MYB, MLX, EP300 | SMN1; SMN2 3158/4885ALDH1A1 235/4885LMNA 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.